| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO and CMO | CEO and Chief Medical Officer | Chief Executive Officer +1 more
1 company
Dirk Thye is CEO and CMO at QNCX. Dirk Thye's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $23.5M at current prices.
Historically, Dirk Thye's trades have earned a middling insider score of 52/100 across 4 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +28.1%.
Net of sales, the QNCX filings show accumulation of 322,500 shares.
Dirk Thye has 12 Form 4 filings on record from March 2016 to January 2026, across 3 companies: CEO and CMO at IRulya Therapeutics (IRLA), 2026; CEO and CMO at Quince Therapeutics (QNCX), 2022–2025; Chief Medical Officer at CDTX, 2016.
The 18 reported transactions were 8 option or other derivative awards, 4 open-market purchases, 2 gifts and 2 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $317K and no sales.
The largest open-market purchase was 88,000 shares of QNCX at an average $1.26 on August 10, 2023, about $111K. Twelve months later QNCX was down 44%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 30, 2024 | QNCX Quince Therapeutics, Inc. | CEO and Chief Medical Officer | Buy | 154,500 | $0.69 | $107,375.00 | +22.4% | +196.7% | +131.5% | |
| Aug 10, 2023 | QNCX Quince Therapeutics, Inc. | Chief Executive Officer | Buy | 88,000 | $1.26 | $110,880.00 | +24.4% | -23.4% | -44.4% | |
| Aug 8, 2023 | QNCX Quince Therapeutics, Inc. | Chief Executive Officer | Buy | 80,000 | $1.24 | $99,200.00 | +28.5% | -21.3% | -43.4% |